# Interleukin-2 (IL-2): T Cell Growth Factor, Treg Maintenance, and the Paradox of Immune Stimulation and Tolerance via IL-2R/JAK1-JAK3/STAT5 Signaling in Research
Discovery: The First T Cell Growth Factor
The IL2 gene maps to chromosome 4q27 in a cytokine cluster alongside IL21 and IL15 (linked by shared receptor chain usage). The mature protein is a 133-amino acid, ~15.5 kDa four-helical bundle cytokine (helices A–D) with a single disulfide bond (Cys58–Cys105) essential for biological activity. IL-2 is produced almost exclusively by recently activated CD4+ T cells (and to lesser extent CD8+ T cells, NKT cells, and innate lymphoid cells) — in response to TCR/CD28 co-stimulation. The transcriptional burst is NFAT-dependent: TCR-activated calcineurin dephosphorylates cytoplasmic NFAT, enabling nuclear translocation and binding to the IL-2 promoter alongside AP-1 (FOS/JUN) and NF-κB. This NFAT dependence is the basis for cyclosporine A (CsA) and tacrolimus (FK506) immunosuppression: both inhibit calcineurin phosphatase → prevent NFAT nuclear entry → suppress IL-2 transcription → block T cell proliferation.
IL-2 mRNA is also subject to post-transcriptional regulation via AU-rich elements (AREs) in the 3' UTR that promote rapid mRNA degradation; TCR/CD28 co-stimulation stabilizes IL-2 mRNA through ARE-binding protein regulation, amplifying the IL-2 secretory burst.
The IL-2 Receptor Complex: Three Chains, Two Configurations
The IL-2 receptor system is uniquely complex, involving three distinct transmembrane chains that assemble into functional receptor complexes with different affinities:
IL-2Rα (CD25, Tac antigen): Encoded by IL2RA on chromosome 10p15.1. A 55 kDa type I transmembrane glycoprotein with a small cytoplasmic domain (13 residues) lacking signaling capacity. CD25 binds IL-2 with low affinity (Kd ~10 nM) but dramatically enhances the affinity of the trimeric complex. CD25 expression is induced on activated T cells within 24 hours of stimulation; constitutively and highly expressed on FOXP3+ regulatory T cells (Tregs). CD25 is the target of basiliximab (anti-CD25 antibody, transplant immunosuppression).
IL-2Rβ (CD122): Encoded by IL2RB on chromosome 22q12.3-13.1. A 75 kDa type I transmembrane glycoprotein with a ~286-residue cytoplasmic domain containing Box1/Box2 motifs for JAK1 binding. CD122 is constitutively expressed on naive CD8+ T cells, NK cells, NKT cells, and memory CD8+ T cells; constitutively expressed at low levels on Tregs.
IL-2Rγ (CD132, common gamma chain, γc): Encoded by IL2RG on chromosome Xq13.1. A 42 kDa type I transmembrane glycoprotein; the signal-transducing chain shared by the receptors for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 — thus named the "common gamma chain." CD132 cytoplasmic domain constitutively associates with JAK3. Mutations in IL2RG cause X-linked severe combined immunodeficiency (X-SCID): T cells fail to develop because IL-7 (T cell development) and IL-2 (T cell expansion) signaling are both abrogated.
Two functional receptor configurations:
1. High-affinity trimeric receptor (IL-2Rαβγ, Kd ~10 pM): Assembled from all three chains; found on activated T cells and constitutively on Tregs. The α chain (CD25) captures IL-2, presenting it to the pre-assembled βγ complex for signaling. The extremely high affinity means that Tregs can compete effectively for scarce IL-2 at nanomolar concentrations in the lymph node, while effector T cells (with lower CD25 expression) require higher local IL-2 concentrations to be activated.
2. Intermediate-affinity dimeric receptor (IL-2Rβγ, Kd ~1–5 nM): Assembled from β+γ chains only; found on resting NK cells, naive CD8+ T cells, and memory CD8+ T cells. Mediates NK cell proliferation/activation and CD8+ T cell homeostatic proliferation at higher IL-2 concentrations; does not bind IL-15 with equivalent affinity (IL-15 uses a distinct IL-15Rα for transpresentation to the shared βγ complex).
Signal Transduction: JAK1/JAK3/STAT5 Core and Accessory Pathways
IL-2Rβ constitutively associates with JAK1; IL-2Rγc constitutively associates with JAK3. IL-2 binding induces βγ chain dimerization → JAK1/JAK3 transphosphorylation → phosphorylation of IL-2Rβ cytoplasmic tyrosines → downstream signaling:
STAT5A/B (primary signal): The dominant IL-2 downstream effector. STAT5 phosphorylation (pY694) creates head-to-tail STAT5 dimers and tetramers that drive expression of:
- •BCL-2, BCL-XL (anti-apoptotic survival)
- •Cyclin D2/D3 (G1/S progression)
- •IL-2Rα (CD25) (positive feedback: IL-2 induces CD25, making cells more sensitive)
- •FOXP3 (in the presence of TGF-β; Treg master transcription factor)
- •Granzyme B, perforin (effector CTL cytotoxic molecules)
Activated STAT5 also induces PIM1/2 kinases and MCL-1 (both anti-apoptotic), and represses the pro-apoptotic BIM (BCL2L11), providing a comprehensive survival package.
PI3K/AKT/mTOR (pY338 on IL-2Rβ → p85→PI3K): Activates mTORC1 → S6K1/4E-BP1 (translational upregulation of biosynthetic enzymes), mTORC2 → AKT S473 → FOXO1/3a nuclear exclusion (anti-apoptotic), and promotes the Warburg metabolic shift in activated T cells. mTOR is critical for effector T cell differentiation; mTOR inhibition (rapamycin) diverts activated T cells toward Treg and memory T cell fates by maintaining FOXO activity.
MAPK/ERK (GRB2/SOS → RAS → RAF → MEK → ERK): ERK1/2 targets include CREB, ELK1, MYC (proliferative), and contributes to cytokine gene regulation; less dominant for IL-2 responses than for TCR signaling per se.
Negative regulation: SOCS1 (a STAT5 transcriptional target) provides rapid feedback inhibition by binding JAK1/JAK3 and targeting them for proteasomal degradation. SHP-1 and SHP-2 phosphatases dephosphorylate JAK1/STAT5. PTPN2 (TC-PTP) is a negative regulator of JAK1; PTPN2 LOF increases IL-2 signaling duration and is a cancer immunotherapy resistance factor (PTPN2 LOF mutations render T cells hypersensitive to IL-2 and IFN-γ).
The IL-2 Paradox: Immune Stimulation vs. Immune Tolerance
IL-2 occupies a uniquely paradoxical position in immunology: it simultaneously drives effector T cell expansion (immune stimulation) and maintains regulatory T cells (immune tolerance). This dual role emerged from several observations:
Mechanism: IL-2 maintains FOXP3+ Tregs: CD4+CD25+FOXP3+ Tregs constitutively express CD25 (IL-2Rα) and are exquisitely dependent on IL-2 for survival and suppressive function. STAT5 activation by IL-2 directly induces and maintains FOXP3 expression. In the absence of IL-2 or CD25, Tregs undergo apoptosis and Treg populations collapse, unleashing autoimmunity. This explains the Il2−/− autoimmune phenotype.
Activation-induced cell death (AICD): IL-2 also sensitizes activated T cells to Fas/FasL-mediated apoptosis — upon restimulation after initial activation, IL-2-primed cells upregulate FasL and become susceptible to fratricide. AICD is the mechanism by which ongoing antigen stimulation terminates T cell responses. This pro-apoptotic role of IL-2 in antigen persistence is separate from its proliferative role during initial priming.
Memory T cell paradox: IL-2 paradoxically inhibits the formation of long-lived memory CD8+ T cells. Blocking IL-2 signaling during initial priming or using partial IL-2 agonists (biased toward βγ, not αβγ) generates more robust memory T cell populations with better recall responses — a key insight for cancer vaccine design.
Aldesleukin (High-Dose IL-2) in Cancer Immunotherapy
Recombinant human IL-2 (aldesleukin, Proleukin) expressed in E. coli as a non-glycosylated 125-amino acid protein (Ala1 substituted for Cys125 to prevent misfolded aggregation) was FDA-approved in 1992 for metastatic renal cell carcinoma and 1998 for metastatic melanoma. The regulatory approval was based on durable complete response rates of 7–9% in both tumor types — unprecedented at the time for metastatic solid tumors.
High-dose IL-2 (600,000–720,000 IU/kg IV bolus every 8 hours × 14 doses per cycle) produces complete responses that are often durable (years), establishing the principle of immunotherapy-induced durable remission. However, the treatment is extremely toxic: vascular leak syndrome (VLS) is the dose-limiting toxicity, manifesting as capillary leakage, hypotension, pulmonary edema, and oliguria requiring ICU management. VLS is mediated by IL-2-activated NK cells releasing IFN-γ and TNF, which disrupts endothelial tight junctions (IL-2 acts directly on endothelial VE-cadherin/CD5L). Treatment requires vasopressors, careful fluid management, and experienced centers. Treatment-related mortality is ~4% in clinical trials.
The durable CR rate vs. extreme toxicity ratio drove intensive research into IL-2 variants that dissociate tumor-killing from toxicity:
Engineered IL-2 Variants: Separating Function from Toxicity
IL-2/anti-IL-2 antibody complexes: Pre-mixing IL-2 with specific anti-IL-2 antibodies dramatically changes biodistribution and receptor selectivity:
- •IL-2 + JES6-1 antibody complex (C1 site, blocking CD122/CD132 but not CD25 binding): preferentially activates CD25+ Tregs → suppresses autoimmunity. Dose: 1–2 µg IL-2 + 5 µg JES6-1, subcutaneous
- •IL-2 + S4B6 antibody complex (blocking CD25-binding site): preferentially activates CD122+CD132+ NK/CD8 cells → anti-tumor immunity without Treg expansion
Nemvaleukin alfa (ALKS 4230): An orthogonal IL-2/IL-2Rα fusion protein that engages CD122/CD132 (intermediate-affinity complex) but not CD25, thereby expanding NK and CD8+ T cells preferentially over Tregs. Clinical trials in solid tumors (NCT02799095).
Rezpegaldesleukin (REZPEG/NKTR-358/LY3471851): Long-acting PEGylated IL-2 conjugate designed to preferentially activate Treg via CD25 engagement — for autoimmune indications (type 1 diabetes, SLE, GVHD). Phase I/II trials in multiple autoimmune conditions.
IL-2 mutein approaches: Point mutations in IL-2 that reduce CD25 affinity (e.g., H16A/F42A mutant: ~50-fold reduced CD25 affinity) bias toward βγ-signaling on NK/CD8 cells over αβγ-signaling on Tregs. These "non-alpha" IL-2 muteins are in Phase I/II for solid tumors.
IL-2/IL-15Rα fusion (IL-2/Fc): Fusion of IL-2 to IgG Fc extends half-life; various orientations affect receptor specificity.
IL-2 in Adoptive T Cell Therapy
IL-2 is the critical survival and expansion factor for ex vivo T cell manufacturing:
CAR-T cell manufacturing: CD3/CD28 bead activation + 300 IU/mL IL-2 drives 1,000-fold T cell expansion over 14 days in culture. IL-2 concentration during manufacturing affects the final CAR-T product phenotype: lower IL-2 concentrations (50 IU/mL) generate more central memory (Tcm) and stem cell memory (Tscm) cells with superior in vivo persistence vs. higher concentrations (300+ IU/mL) that generate more effector-differentiated cells.
TIL (tumor-infiltrating lymphocyte) therapy: High-dose IL-2 (720,000 IU/kg) is administered systemically after TIL infusion to support TIL expansion and persistence in vivo — the major toxicity driver of this approach. Lifileucel (AMTAGVI) TIL therapy with IL-2 support received FDA accelerated approval in February 2024 for metastatic melanoma — the first TIL therapy approval.
NK cell therapy: Recombinant IL-2 or IL-15 is required for NK cell activation, expansion, and cytotoxicity in vitro; subcutaneous IL-2 administration post-NK infusion supports NK survival in vivo, though with limited NK engraftment compared to IL-15.
XSCID: The Common Gamma Chain and JAK3 Connection
X-linked severe combined immunodeficiency (X-SCID) results from loss-of-function mutations in IL2RG (common gamma chain, γc) — the most common form of SCID. Without γc, T cells cannot develop (IL-7/IL-7R/γc → JAK1/JAK3 → STAT5 required for thymocyte development) and NK cells are absent; B cells develop but are non-functional. The T-B+NK- SCID immunophenotype is pathognomonic for γc deficiency.
Autosomal recessive JAK3 deficiency causes an identical phenotype to X-SCID (T-B+NK- SCID) — validating that JAK3 is the exclusive downstream kinase for the γc chain. Gene therapy for X-SCID using γ-retroviral or lentiviral vectors delivering IL2RG cDNA has been curative in most patients, though early trials with γ-retroviral vectors caused T cell leukemia due to insertional mutagenesis near proto-oncogenes (e.g., LMO2) — a safety crisis resolved by safer lentiviral self-inactivating vectors and genomic safe harbor site-specific insertion approaches.
Research Tools and Experimental Models
| Tool | Application | Key Detail |
|---|---|---|
| Il2−/− mice | IL-2 tolerance requirement | Lethal autoimmune colitis + hemolytic anemia within 4-8 weeks |
| Il2ra−/− (CD25−/−) mice | Treg IL-2R dependence | Similar autoimmune phenotype; Tregs collapse |
| Il2rg−/− (gamma chain−/−) mice | SCID modeling | T-B+NK- SCID; basis for NSG/NOG humanized mouse models |
| NSG/NOG mice | Human immune system engraftment | Il2rg−/−; lack of γc prevents rejection of human immune cells; standard xenograft model |
| FOXP3-GFP/Cre reporter mice | Treg lineage tracing | Fate mapping of FOXP3+ Treg; activated by IL-2/STAT5 |
| Anti-IL-2 antibody complexes (JES6-1/S4B6) | Biased IL-2 delivery | Treg expansion (JES6-1) vs NK/CD8 expansion (S4B6) |
| Aldesleukin (IL-2) | T cell proliferation assay | 10–100 IU/mL stimulates T cell proliferation in vitro; anti-tumor NK activation |
| STAT5 phospho-flow (pY694) | IL-2 signaling readout | Rapid 15-min kinetic assay in whole blood or PBMC |
| pSTAT5 ELISA | IL-2 receptor signaling quantification | IC50 determination for IL-2 variants and antagonists |
| IL-2 reporter (GFP/luciferase under IL-2 promoter) | TCR/calcineurin/NFAT activity sensor | Cyclosporine dose-response; NFAT pathway inhibitor screening |
Current Research Frontiers
Orthogonal IL-2/IL-2R pairs: Protein engineering of IL-2 and IL-2Rβ mutations that form a "designer" ligand-receptor pair orthogonal to endogenous IL-2 — enabling synthetic control of specific T cell subpopulations in vivo without affecting endogenous IL-2 responses. Daniel Chen/Wendell Lim UCSF work on orthogonal cytokine-receptor pairs.
IL-2 antibody fusion proteins for tumor targeting: Fusion of IL-2 to tumor-targeting antibodies (anti-CEA, anti-FAP) concentrates IL-2 in the tumor microenvironment, improving the therapeutic index vs. systemic aldesleukin by limiting Treg activation and VLS. Cergutuzumab amunaleukin (FAP-IL-2v, Roche) is in Phase I/II for solid tumors.
IL-2 fusion with checkpoint inhibitors: Bifunctional antibodies combining IL-2 activity with PD-1 blockade aim to concentrate IL-2-driven T cell expansion at the tumor site while releasing the PD-1 brake simultaneously.
Treg-based cell therapy: Ex vivo expansion of Tregs using IL-2 (low-dose) + rapamycin (preserves Treg identity vs. effector contamination) + CD3/CD28 stimulation generates large numbers of Tregs for infusion in GVHD, organ transplant tolerance, and autoimmune disease Phase I/II trials.
Conclusion
Interleukin-2 remains one of the most conceptually rich cytokines in immunology — simultaneously the prototypical T cell growth factor and the critical Treg survival cytokine, embodying the fundamental tension between immunity and tolerance. Its 1976 discovery as the first T cell growth factor enabled decades of cellular immunology research and the first durable complete remissions in metastatic cancer via high-dose aldesleukin. The discovery that Il2−/− mice develop autoimmunity rather than immunodeficiency fundamentally reframed our understanding of IL-2 biology from growth factor to tolerance mediator. The elaborate signaling architecture — trimeric vs. dimeric receptors, JAK1/JAK3/STAT5 axis, NFAT-dependent gene induction — provides a mechanistic framework for the next generation of engineered IL-2 variants that promise safer, more effective immunotherapy by selectively harnessing IL-2's tumor-killing capacity while minimizing Treg activation and vascular toxicity.
References
1. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science. 1976;193(4257):1007-1008. PMID: 181845
2. Taniguchi T, Matsui H, Fujita T, et al. Structure and expression of a cloned cDNA for human interleukin-2. Nature. 1983;302(5906):305-310. PMID: 6403867
3. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell. 1993;75(2):253-261. PMID: 8402910
4. Willerford DM, Chen J, Ferry JA, et al. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity. 1995;3(4):521-530. PMID: 7584142
5. Smith KA. Interleukin-2: inception, impact, and implications. Science. 1988;240(4851):1169-1176. PMID: 3131876
6. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105-2116. PMID: 10561265
7. Lenardo MJ. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature. 1991;353(6347):858-861. PMID: 1944573
8. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science. 2006;311(5769):1924-1927. PMID: 16484453
9. Abbas AK, Trotta E, Simeonov DR, et al. Revisiting IL-2: Biology and therapeutic prospects. Sci Immunol. 2018;3(25):eaat1482. PMID: 29980617
---
FOR RESEARCH USE ONLY. Not for human or veterinary use. Not for diagnostic or therapeutic applications. All biological activity data are derived from in vitro and preclinical studies; results may not predict human clinical outcomes. Information is provided for educational and research purposes only.